Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma
BackgroundLower-grade glioma (LGG) exhibits significant heterogeneity in clinical outcomes, and current prognostic markers have limited predictive value. Despite the growing recognition of histone modifications in tumor progression, their role in LGG remains poorly understood. This study aimed to de...
Saved in:
Main Authors: | Jingyuan Wang, Shuai Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1523779/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pan-cancer analysis of the transcriptional expression of histone acetylation enzymes in solid tumors defines a new classification scheme for gliomas
by: Junhao Zhang, et al.
Published: (2025-01-01) -
Comprehensive analysis reveals cholesterol metabolism-related signature for predicting prognosis and guiding individualized treatment of glioma
by: Dengfeng Lu, et al.
Published: (2025-01-01) -
An exceptionally rare case of a diffuse midline glioma with concomitant H3.1 K27M and G34R mutations in the HIST1H3C (H3C3) gene
by: Zita Reisz, et al.
Published: (2025-01-01) -
Prognostic factors of thalamic and thalamopeduncular low-grade gliomas in children: A systematic review and recommendations for surgical management
by: Jana Táborská, et al.
Published: (2025-01-01) -
Identification of CDKN3 overexpression as a marker of poor prognosis and potential therapeutic target in low-grade glioma
by: Hongbing Cheng, et al.
Published: (2025-01-01)